Back to search

Ireland· IE-PA-EU/1/24/1893/001-002

WELIREG 40 mg film-coated tablets

A belzutifan product containing belzutifan, registered in Ireland by Merck Sharp & Dohme BV,. The same ATC class is registered in 14 of our 19 countries.

ATC L01XX74

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedWELIREG 40 mg film-coated tabletsATCL01XX74REGISTER NO.IE-PA-EU/1/24/1893/00…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Belzutifan is registered in 14 of 19 countries.

Countries holding a registration under ATC L01XX74 (belzutifan), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Belzutifan · ATC L01XX74

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of belzutifan costs, country by country.

Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Belzutifan · price per daily dose (0.12 g)

USD · FX 28 Sept 2026

  • FR France$0.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Belzutifan
Manufacturer
Merck Sharp & Dohme BV,
Country
Ireland (IE)
ATC code
L01XX74
ATC class
Belzutifan
Defined daily dose
0.12 g, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/24/1893/001-002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Belzutifan in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All belzutifan products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Welireg
  • Liechtenstein · Welireg
  • Norway · Welireg

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/453c3884-a8dd-413d-a9d1-4c38c655b35c
GET /v1/drugs/453c3884-a8dd-413d-a9d1-4c38c655b35c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XX74"
  ],
  "strength": null,
  "pa_number": "EU/1/24/1893/001-002",
  "substances": [
    "Belzutifan"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "12/02/2025",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about belzutifan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.